Barclays Initiates Coverage On Indivior Pharmaceuticals with Overweight Rating, Announces Price Target of $46

Benzinga Newsdesk www.benzinga.com Neutral 50.3%

Neg 0% Neu 50.3% Pos 0%

Barclays analyst Glen Santangelo initiates coverage on Indivior Pharmaceuticals (NASDAQ:INDV) with a Overweight rating and announces Price Target of $46.